OncoCyte
Stock Forecast, Prediction & Price Target
OncoCyte Financial Estimates
OncoCyte Revenue Estimates
OncoCyte EBITDA Estimates
OncoCyte Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $7.72M N/A | $958K -87.60% | $1.50M 56.88% | Avg: $4.82M Low: $2.68M High: $6.98M avg. 221.25% | Avg: $11.3M Low: $8.52M High: $14.07M avg. 134.02% | ||
Net Income
% change YoY
| $-64.09M N/A | $-73.44M -14.57% | $-27.78M 62.17% | Avg: $-20.62M Low: $-19.73M High: $-6.80M avg. 25.76% | Avg: $-19.1M Low: $-14.33M High: $-7.39M avg. 7.39% | ||
EBITDA
% change YoY
| $-16.84M N/A | $-30.39M -80.46% | $-23.12M 23.93% | Avg: $-2.89M Low: $-4.19M High: $-1.61M avg. 87.47% | Avg: $-6.78M Low: $-8.44M High: $-5.11M avg. -134.02% | ||
EPS
% change YoY
| -$14.42 N/A | -$13.26 8.04% | -$3.75 71.71% | Avg: -$1.7 Low: -$2.58 High: -$0.89 avg. 54.66% | Avg: -$1.42 Low: -$1.87 High: -$0.97 avg. 16.47% | ||
Operating Expenses
% change YoY
| $47.13M N/A | $30.31M -35.68% | $25.63M -15.42% | Avg: $55.82M Low: $31.02M High: $80.75M avg. 117.73% | Avg: $130.63M Low: $98.56M High: $162.70M avg. 134.02% | ||
FAQ
What is OncoCyte stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.57% in 2025-2026.
We have gathered data from 2 analysts. Their low estimate is -19.73M, average is -20.62M and high is -6.80M.
What is OncoCyte stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 177.64% in 2025-2026.
We have gathered data from 2 analysts. Their low revenue estimate is $2.68M, average is $4.82M and high is $6.98M.
What is OncoCyte stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 35.56% in 2025-2026.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$2.58, average is -$1.7 and high is $-0.89.
What is the best performing analyst?
In the last twelve months analysts have been covering OncoCyte stock. The most successful analyst is Mike Matson.